Anhedonia – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:16:35 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Anhedonia – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on Pramipexole for Reducing Anhedonia in Patients with Major Depression https://clinicaltrials.eu/trial/study-on-pramipexole-for-reducing-anhedonia-in-patients-with-major-depression/ Wed, 29 Apr 2026 15:05:26 +0000 https://clinicaltrials.eu/trial/study-on-pramipexole-for-reducing-anhedonia-in-patients-with-major-depression/ This clinical trial is focused on studying the effects of the medication Pramipexole on symptoms of anhedonia in individuals with major depression. Anhedonia is a condition where a person finds it difficult to feel pleasure in activities they usually enjoy. The study aims to determine if treatment with Pramipexole can reduce these symptoms over a nine-week period when compared to a placebo. Pramipexole is administered in the form of a prolonged-release tablet, which means it releases the medication slowly over time to maintain a steady level in the body.

Participants in the study will receive either Pramipexole or a placebo and will be monitored over the course of nine weeks. The maximum dosage of Pramipexole will be 3.15 milligrams per day, adjusted to avoid any intolerable side effects. The study will involve regular assessments to track changes in anhedonia symptoms and other related measures. These assessments will include questionnaires and possibly the use of activity meters to measure physical activity and sleep patterns. Additionally, some participants may undergo brain imaging techniques like fMRI to observe brain activity related to pleasure and reward.

The purpose of this study is to explore whether Pramipexole can be an effective additional treatment for reducing anhedonia in people with major depression. By comparing the effects of Pramipexole to a placebo, researchers hope to gain insights into its potential benefits and any side effects. The study is expected to continue until December 2026, with the goal of improving treatment options for those experiencing anhedonia as part of their depression.

]]> Study on Aticaprant and Antidepressant for Preventing Relapse in Adults with Major Depressive Disorder and Anhedonia https://clinicaltrials.eu/trial/study-on-aticaprant-and-antidepressant-for-preventing-relapse-in-adults-with-major-depressive-disorder-and-anhedonia/ Wed, 29 Apr 2026 14:57:39 +0000 https://clinicaltrials.eu/trial/study-on-aticaprant-and-antidepressant-for-preventing-relapse-in-adults-with-major-depressive-disorder-and-anhedonia/ This clinical trial is focused on studying Major Depressive Disorder (MDD), a condition characterized by persistent feelings of sadness and loss of interest. The study specifically targets individuals with moderate-to-severe anhedonia, which is a reduced ability to feel pleasure. The treatment being tested is a medication called Aticaprant, which is taken in tablet form. It is used alongside an antidepressant, which is a type of medication that helps to relieve symptoms of depression. The purpose of the study is to evaluate how effective Aticaprant is in preventing the return of depressive symptoms in people who have already shown improvement with their current treatment.

Participants in the study will be randomly assigned to receive either Aticaprant or a placebo, which looks like the medication but does not contain the active substance. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual medication or the placebo. This helps to ensure that the results are not influenced by expectations about the treatment. The study will take place over a period of time, during which participants will continue their usual antidepressant treatment while also taking the study medication or placebo.

The main goal is to see how long it takes for depressive symptoms to return, if they do, after starting the study treatment. This information will help researchers understand if Aticaprant can effectively delay the relapse of depression symptoms in people with MDD and anhedonia. Participants will be monitored regularly to assess their response to the treatment and to ensure their safety throughout the study.

]]>